Blue Matter Blog
November 8, 2019
The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team. These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The third Breakfast Club meeting was on 5th November 2019 at Skylounge restaurant in Zug, Switzerland. …
January 28, 2019
Regardless of the product, launching a new biopharmaceutical drug is a time-consuming, expensive, and complex undertaking. It requires sound strategy, expert planning, and effective cross-functional coordination to get everything done right. The analogy is certainly not new but launch really is akin to conducting a symphony orchestra, ensuring that all members play their parts correctly, …
November 7, 2018
Part Two in a Six-Part Series on Oncology Product Commercialization In Part One, we mentioned that the launch frequency for oncology products has increased significantly over the last several years. While this trend is seen in other therapeutic areas across the industry, we believe the combination of factors driving this in oncology are somewhat unique …
As a founder and managing partner, Ashwin brings 18+ years of life science consulting experience to Blue Matter. Prior to starting Blue Matter, he was Senior VP, Head of Brand Management / Business Development at Campbell Alliance. He is a physician and MBA by training and his specialties include product and portfolio strategy.
As a founder and managing partner of Blue Matter, Emily brings 21 years of life science experience. Prior to Blue Matter, Emily was Senior VP and head of the San Francisco office for Campbell Alliance. Her specialties include product and portfolio strategy and oncology product launches.
As head of Blue Matter Europe, George brings extensive experience from 17+ years in life science consulting. Previously, George was GM / Head of Europe for Campbell Alliance. His specialties are commercial excellence, organizational design and customer engagement strategy.
Jeron brings 16+ years of life science experience, including more than 11 years in consulting. Previously, Jeron was Corporate Development and Commercial Excellence Lead at Campbell Alliance. His specialties include product, portfolio, and corporate strategy in oncology and diagnostics.
Thomas has 12+ years of experience in life science consulting (bio-pharma / diagnostic). He was formerly VP of Brand Management and Medical Affairs at Campbell Alliance. His specialties include product commercialization and Medical Affairs organization development in oncology and rare diseases.
Pankaj brings an impressive 26+ years of life science experience in industry and consulting to Blue Matter, having held increasingly senior positions at GSK, Bristol-Myers Squibb and Norgine. He was formerly Head of Consulting at IDEA, and he specializes in product, franchise and portfolio strategy, new product planning, and oncology launch readiness. He holds a BSc Pharm from UCL and an MBA from Imperial College London.
With over 11 years in research and consulting for the life sciences, Mary’s primary focus is on product strategy, franchise/portfolio strategy, launch planning, and commercial excellence in oncology and other TAs. She has a PhD in Biology from MIT and also hails from Campbell Alliance.
Kurt is a seasoned expert in market access, with over 23 years of experience. In addition to his extensive experience in life sciences consulting, his background includes several strategic roles across both payers and biopharmaceutical companies (large and small). He earned his undergraduate degree from the University of California, Los Angeles and his JD from Pepperdine University.
Martin brings 20 years of Life Sciences Consulting experience to his work. Responsible for leading Blue Matter’s business in the eastern US, he is a specialist in commercial strategy and pharmaceutical launch. Prior to joining Blue Matter, Martin served clients at ZS Associates and Navigant (Guidehouse). He earned his MBA from the European Business School in Germany as well as the University of Pittsburgh.
Alex has more than 13 years of experience consulting to life science companies. He brings deep expertise in market research and analytics, particularly related to commercial strategy development. Before joining Blue Matter, Alex spent three years at Campbell Alliance and five years at ZS Associates. He earned an MS degree in Management Science from Lehigh University and a degree in Engineering from Lafayette College.
Shankar brings strong scientific and commercial expertise to his consulting work. In his 9+ years in life sciences consulting, he has delivered broadly, including product launch and portfolio strategy across oncology and other therapeutic areas. Shankar earned a BA in Molecular and Cellular Biology from the University of California at Berkeley and a PhD in Biochemistry from MIT.
Matt Durbin brings more than 13 years of life sciences experience to his role at Blue Matter, including 10 years in strategic consulting. Prior to joining Blue Matter, he worked as a consultant for IMS Health. In addition to his consulting experience, Matt spent 3 years performing research at the University of Oxford. He earned a Ph.D. in organic chemistry from the University of Bath.
Isabel has more than 10 years of experience in life science research and strategy consulting. Her work focuses on integrated product and diagnostic strategy, disease area strategy, and launch readiness in oncology. She brings a strong educational background in neuroscience, having earned a Ph.D. in Neuroscience from ETH Zurich. Isabel also has a Certificate of Advanced Studies in Design Thinking.
With more than 15 years in the life sciences, Theo's experience spans from bench to business strategy. For the past 10 years, Theo has provided consulting services to help biopharma companies achieve commercial success in Europe and North America. He leads Blue Matter’s “Pathfinder” business line, which specializes in helping biopharma companies enter and succeed in European markets. Theo earned a Dr. sc. In Physical Chemistry from ETH Zürich and an MBA from IMD Business School.